Effectiveness and Safety of Tauractant in the Treatment of Drug-Resistant Respiratory Tuberculosis
Open Access
- 15 July 2025
- journal article
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 103 (3) , 24-31
Abstract
The objective: to evaluate effectiveness and safety of inhaled highly purified tauractant as a pathogenetic agent in the treatment of pulmonary tuberculosis with multiple, pre-extensively and extensively drug resistance.Subjects and Methods. 104 patients with drug-resistant tuberculosis were included in the study, 29 of them were HIV-positive. Patients received chemotherapy (CT) according to the regimen for drug-resistant tuberculosis (MDR, pre-MDR, and MDR) based on the individual drug susceptibility of Mycobacterium tuberculosis (MTB). Tauractant was administered by inhalation in the form of a lyophilisate for the emulsion preparation. The patients were randomized into 2 groups: In CT+ST Group (n=52), surfactant therapy was prescribed in addition to chemotherapy, using tauractant in the form of Surfactant BL (Russia) at a dose of 25 mg according to the regimen [5], in CT Group (n=52), only chemotherapy was administered.Results. By the end of 2 months of chemotherapy, respiratory symptoms resolved in 35/39 (89.7%) patients in CT+ST Group, and in 22/33 (66.7%) in CT Group (p<0.05). Positive X-ray changes were observed in 39/52 (75.0%) patients in CT+ST Group and in 28/52 (53.8%) patients in CT Group, (p<0.05), and healing of cavities was observed in 9/30 (30.0%) and 2/33 (6.1%) (p<0.05) patients, respectively. The trend toward faster sputum conversion (by culture) and healing of cavities persisted throughout the study period in CT+ST Group versus CT Group. In the patients from cavernous and fibrous cavernous tuberculosis subgroup of CT+ST Group, cavities healed more frequently (size up to 3 cm) by week 8 of treatment versus the same subgroup of CT Group. No serious adverse reactions were observed during the study, and no connection between adverse reactions and the use of tauractant was established.Keywords
This publication has 5 references indexed in Scilit:
- Immunohistochemical evaluation of surfactant-associated protein in fibrosis-cavernous pulmonary tuberculosisInnovative Medicine of Kuban, 2019
- Homo- and hetero-oligomerization of hydrophobic pulmonary surfactant proteins SP-B and SP-C in surfactant phospholipid membranesJournal of Biological Chemistry, 2018
- The Role of Surfactant in Lung Disease and Host Defense against Pulmonary InfectionsAnnals of the American Thoracic Society, 2015
- Transcriptional responses of Mycobacterium tuberculosis to lung surfactantMicrobial Pathogenesis, 2009
- Lung Surfactant and Its Use in Lung DiseasesGeneral Reanimatology, 2007